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Abstract
The European Committee on Antimicrobial Susceptibility Testing-
Subcommittee onAntifungal Susceptibility Testing (EUCAST-AFST)
has determined breakpoints for posaconazole for Candida spp. This
Technical Note is based on the EUCAST posaconazole rationale
document (available on the EUCAST website: http://www.
eucast.org). Species-speciﬁc breakpoints for C. albicans, C. parapsilo-
sis and C. tropicalis are S: MIC £0.06 mg/L, R: MIC >0.06 mg/L. There
are insufﬁcient data to set breakpoints for C. glabrata and C. krusei
as well as non-species-related breakpoints. The breakpoints are
based upon pharmacokinetic data, epidemiological cut-off values
and clinical experience. Breakpoints will be reviewed regularly.
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Introduction
Posaconazole is a triazole antifungal agent active in vitro
against Candida spp. and Cryptococcus spp. as well as Aspergil-
lus spp. and certain other moulds. The drug is approved for
the following indications: (i) refractory invasive fungal dis-
eases including aspergillosis, fusariosis, chromoblastomycosis,
coccidioidomycosis and mycetoma, (ii) ﬁrst-line therapy for
the treatment of oropharyngeal candidiasis of patients who
have severe disease or who are immunocompromized, for
whom a response to topical therapy is expected to be poor
and (iii) the prophylaxis of invasive fungal disease of patients
receiving remission-induction chemotherapy for acute mye-
logenous leukaemia or myelodysplastic syndromes as well as
for haematopoietic stem cell transplant recipients with graft
vs. host disease.
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for posacona-
zole for Candida spp. This Technical Note is based on the
EUCAST posaconazole rationale document (available on the
EUCAST website: http://www.eucast.org). The rationale doc-
ument includes more detail and published references related
to the selection of EUCAST-AFST breakpoints (http://
www.srga.org/eucastwt/MICTAB/EUCAST%20clinical%20MIC%
20breakpoints%20-%20antimicrobials%20for%20Candida%20
infections.htm).
The breakpoints are based on licensed dosing of
100 mg · 1, 200 mg · 3, 200 mg · 4 and 400 mg · 2 for
mucosal infection and were established using MIC values
from many sources. Wild-type isolates exhibits MICs of
C. albicans, C. parapsilosis and C. tropicalis £0.064 mg/L, C. glab-
rata £1 mg/L, C. krusei £0.5 mg/L and C. guilliermondii
£0.25 mg/L. The clinical data from four clinical trials on
mucosal candidosis in HIV patients were used [1–3 and Data
on File (Schering-Plough, Kenilworth, NJ, USA). The dataset
included 488 C. albicans, 11 C. glabrata, 4 C. krusei and 3
C. tropicalis. MICs were determined by a reference labora-
tory. There were 448 (88.5%) successes and 58 (11.5%) fail-
ures. For C. albicans the rate of response was 89.3%. These
studies did not include MICs by the EUCAST method so a
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correlation of in vitro MICs with clinical outcome is not pos-
sible. Furthermore, there is no clinical evidence that cases
involving isolates with acquired resistance mechanisms
respond to treatment, hence the EUCAST breakpoints,
which are summarized in Table 1, are based upon pharmaco-
kinetic data, epidemiological cut-off values and clinical experi-
ence [1–6]. Breakpoints will be reviewed regularly.
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TABLE 1. Species-speciﬁc Posaconazole EUCAST break-
points
Speciesa,b Species-related breakpointsb (mg/L)
C. albicans S £ 0.06 R > 0.06
C. parapsilosis S £ 0.06 R > 0.06
C. tropicalis S £ 0.06 R > 0.06
aThere is insufﬁcient evidence to set non-species-related breakpoints.
bEpidemiological cut-off values for C. glabrata, C. guilliermondii and C. krusei are 1,
0.25 and 0. 5 mg/L, respectively, 2–4 two-fold dilutions higher than those for
C. albicans, C. parapsilosis and C. tropicalis. In addition, the small number of cases
in the clinical trials means that there is insufﬁcient evidence to indicate whether
the wild-type populations of these pathogens can be considered as susceptible
to posaconazole. Hence, for C. glabrata, C. guilliermondii and C. krusei there is
insufﬁcient evidence to set breakpoints.
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